Tag: clinical phase 2 trial
Anaphylm™, Aquestive’s Needleless Sublingual Epinephrine, Takes Another Step Forward
Company reports positive topline results from phase 2 study.
Aravax Doses First Patient in Phase 2 Peanut Allergy Clinical Trial
PVX108 does not contain peanut proteins which put patients at risk of serious side effects.
Peptide Shows Promise as an Allergen-Agnostic Treatment for Food Allergy
Revolog presents new data demonstrating long-lasting effect of '1104 candidate.
Novel Peanut Allergy Treatment Shown to be Safe, Effective, and Lasting
A unique peanut allergy immunotherapy continues to show promise for children.
Study of Boiled Peanuts Show Promise for Treatment of Peanut Allergy
OIT with boiled followed by roasted peanuts appears effective with a favorable safety profile.
Company Completes Enrollment for Phase 2 Trial of “Immune Resetting” Peptide...
Topline data anticipated in Q2 2023.
Aquestive Receives Positive FDA Response to Epinephrine Sublingual Film Phase 2...
Response confirms approach and supports the characterization of their novel drug platform.
Aquestive’s Sublingual Emergency Epinephrine Compares Favorably to EpiPen® in EPIPHAST II...
The company announced topline results from their EPIPHAST II study.
Siolta Begins Phase 2 Study in Newborns of Bacteria Consortia ...
STMC-103H has a combination of bacteria that are depleted in the gut microbiota of infants who go on to develop allergic sensitization and allergic diseases in childhood.
Aquestive Reports Positive Results from Sublingual Epinephrine Clinical Trial
Phase 2 study continues to show AQST-109 is safe and well tolerated.
